01477.HK
Ocumension Therapeutics
HKSE · Healthcare · Biotechnology · CN
HKD 5.37
+1.23%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−14.8x
Market Cap
HKD 4.40B
MomentumView details →
1D Return
+1.23%
YTD Return
−27.50%
RSI (14)
52.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−14.8x
Market Cap
HKD 4.40B
RSI (14)
52.0
MomentumView details →
1D Return
+1.23%
YTD Return
−27.50%
Similar companies
Latest newsMore news →
Ocumension Therapeutics announced that the Phase III clinical trial of OT-211 (TRYPTYR acotiamide eye drops) in China has completed enrollment of 398 patients.2d agoOcumension Therapeutics announced that the first patient has been enrolled in the Phase III clinical trial of OT-202 for dry eye disease in China.4d agoNicox's exclusive licensee Ocumension received positive pre-submission regulatory feedback from the Chinese Center for Drug Evaluation for NCX 470, supporting a planned NDA submission in China.79d ago